Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis
Clinical and Translational Allergy · 2023-05 · 13 (5)
DOI: 10.1002/clt2.12245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Allergy, online erschienen am 06.05.2023. Verfasst von Oliver Pfaar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, Philipps-Universität Marburg, University Hospital Marburg…. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: LETI Pharma, Germany.
Abstract (Originalsprache)
Introduction
Allergic rhinitis (AR) is a widespread disease with increasing prevalence in developed countries. The only treatment that tackles the underlying causes is allergen immunotherapy (AIT). This treatment is performed through two application routes, the subcutaneous immunotherapy (SCIT) or the sublingual immunotherapy (SLIT). However, persistence during the long course of treatment over 3 years is key for the efficacy of this treatment option. The impaired adherence significantly impacts public health resources. The aim of this study was to assess the persistence of AIT for both application routes.
Methods
IQVIA TM LRx was used to identify patients starting AIT between 2009 and 2018 with grass pollen (GP), early flowering tree pollen (EFTP) and house dust mite (HDM) allergens. Patients were classified within each allergen category by AIT groups (subcutaneous depigmented polymerised allergen AIT [dSCIT], other subcutaneous AIT [oSCIT] and SLIT) and age (5‐11 years, 12‐17 years, 18+ years). Furthermore, they were followed up for up to 3 years until the cessation of treatment. Patients, who were still on treatment after 3 years were deemed to be censored. Kaplan‐Meier curves of persistence were generated and compared by log‐rank tests.
Results
The number of patients included in the three allergen categories was 38,717 GP, 23,183 EFTP, and 41,728 HDM AIT. In all allergen categories and for any product group, patient persistence decreased with increasing age class with the difference between 5‐11 years and 12‐17 years greater than between the latter and 18+ years. The percentage of patients completing the first year of AIT was low, particularly for SLIT where 22.2%–27.1% of patients remained persistent after 12 months. The equivalent figures for dSCIT were 52.0%–64.1% and for oSCIT 38.3%–50.3%.
Conclusion
Persistence in AIT in AR was low in this retrospective prescription‐based database and was clearly linked to patient age and application route.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, Philipps-Universität Marburg, University Hospital Marburg, Marburg, Germany.
- Epidemiology, IQVIA, Frankfurt, Germany.
- LETI Pharma GmbH, Ismaning, Germany.
- Department of Clinical Immunology, Wroclaw Medical University, Wroclaw, Poland.
- ALL-MED Medical Research Institute, Wroclaw, Poland.
ORCID-Profile: Oliver Pfaar
Förderung
- LETI Pharma, Germany
Zitieren
APA
Pfaar, O., Richter, H., Sager, A., Miller, C., Müller, T., & Jutel, M. (2023). Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis. Clinical and Translational Allergy, 13(5). https://doi.org/10.1002/clt2.12245
Vancouver
Pfaar O, Richter H, Sager A, Miller C, Müller T, Jutel M. Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis. Clinical and Translational Allergy. 2023;13(5). doi:10.1002/clt2.12245
BibTeX
@article{Pfaar2023,
author = {Pfaar, Oliver and Richter, Hartmut and Sager, Angelika and Miller, Christoph and Müller, Thomas and Jutel, Marek},
title = {Persistence in allergen immunotherapy: A longitudinal, prescription data‐based real‐world analysis},
journal = {Clinical and Translational Allergy},
year = {2023},
volume = {13},
number = {5},
doi = {10.1002/clt2.12245}
}
EUVIMED